Additional file 1: of Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients

Table S1. Association between biomarkers at baseline, clinical covariates and progression free survival for metastatic melanoma patients. Figure S1. Kaplan-Meier analysis of progression free survival in ipilimumab treated melanoma patients. Figure S2. Kaplan-Meier analysis of overall survival in ipilimumab treated melanoma patients. Figure S3. Correlation between the C3M/PRO-C3 ratio and levels of C3M or PRO-C3 in the individual melanoma patients. Table S2. Biomarker levels in serum at baseline and 3 weeks after ipilimumab treatment. (DOCX 238 kb